Oramed Pharmaceuticals (ORMP) Return on Capital Employed (2011 - 2026)
Oramed Pharmaceuticals (ORMP) posted Return on Capital Employed of 5.95% for Q1 2026, up 18.48% on a QoQ basis from 7.3% in Q4 2025, and up 386.0% year-over-year from 1.23% in Q1 2025.
Oramed Pharmaceuticals (ORMP) Return on Capital Employed (2011 - 2026) Analysis & Trends
Oramed Pharmaceuticals' Return on Capital Employed history runs 15 years deep, the most recent figure standing at 5.95% for Q1 2026.
- Quarterly Return on Capital Employed rose 386.0% year-over-year to 5.95% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 5.95% (up 386.0% YoY) and the FY2025 annual result came in at 8.67%, down 166.0% from the prior year.
- Return on Capital Employed was 5.95% for Q1 2026 at Oramed Pharmaceuticals, up from 7.3% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 5.95% in Q1 2026 and bottomed at 35.12% in Q3 2022.
- A 5-year average of 15.24% and a median of 9.14% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed soared 1831 bps — and 2025, when it plunged 230 bps.
- Oramed Pharmaceuticals' Return on Capital Employed stood at 27.45% in 2022, then soared by 67 bps to 9.14% in 2023, then grew by 9 bps to 8.27% in 2024, then rose by 12 bps to 7.3% in 2025, then rose by 18 bps to 5.95% in 2026.
- Business Quant data shows ORMP's Return on Capital Employed at 5.95% in Q1 2026, 7.3% in Q4 2025, and 7.03% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Oramed Pharmaceuticals | 170.25 Mn | 170.25 Mn | - | -5.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.95% |
| Dec 31, 2025 | -7.30% |
| Sep 30, 2025 | -7.03% |
| Jun 30, 2025 | -9.06% |
| Mar 31, 2025 | -9.81% |
| Dec 31, 2024 | -8.27% |
| Sep 30, 2024 | -7.71% |
| Jun 30, 2024 | -6.76% |
| Mar 31, 2024 | -7.57% |
| Dec 31, 2023 | -9.14% |
| Sep 30, 2023 | -20.98% |
| Jun 30, 2023 | -18.80% |
| Mar 31, 2023 | -23.85% |
| Dec 31, 2022 | -27.45% |
| Sep 30, 2022 | -35.12% |
| Jun 30, 2022 | -30.66% |
| Mar 31, 2022 | -23.54% |
| Aug 31, 2021 | -33.90% |
| Nov 30, 2019 | -43.95% |
| Aug 31, 2019 | -47.60% |